Key result
TAVR linked to ~36% lower 30-day mortality vs. SAVR in dialysis-dependent severe AS patients.
Why the study?
The optimal treatment strategy for severe AS in dialysis-dependent patients remains uncertain.
Does transcatheter aortic valve replacement reduce 30-day all-cause mortality compared to surgical aortic valve replacement in dialysis-dependent adults with severe aortic stenosis?
Meta-Analysis (n=13,312)
Does transcatheter aortic valve replacement reduce 30-day all-cause mortality compared to surgical aortic valve replacement in dialysis-dependent adults with severe aortic stenosis?
In dialysis-dependent patients with severe aortic stenosis, TAVR is associated with lower 30-day mortality and shorter hospital stays compared to SAVR, though with higher rates of pacemaker implantation and vascular complications.
Answers are grounded in this paper and cite their sources.
May support TAVR preference for lower early mortality in dialysis-dependent severe AS; leaves open randomized confirmation of observational findings.
The optimal treatment strategy for severe aortic stenosis (AS) in dialysis-dependent patients remains uncertain. We conducted an updated systematic review and meta-analysis comparing transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement, with certainty assessed using GRADE. PubMed, Embase, and Cochrane were searched from inception through June 2026 for comparative studies in dialysis-dependent adults with severe AS. The primary outcome was 30-day all-cause mortality, while secondary outcomes included stroke, myocardial infarction, major bleeding, major vascular complications, permanent pacemaker implantation, and intensive care unit and hospital length of stay. Random-effects models were used, with prespecified subgroup and sensitivity analyses. Eight observational studies involving 13,312 patients were included. TAVR was associated with lower 30-day mortality than surgical aortic valve replacement (risk ratio [RR], 0.64; 95% confidence interval [CI], 0.42–0.98; I 2 = 88%), although this association was confined to adjusted studies. TAVR was also associated with shorter intensive care unit stay (mean differences, −3.63 days; 95% CI, −5.10 to −2.15) and hospital stay (mean differences, −5.37 days; 95% CI, −8.83 to −2.23), but higher risks of permanent pacemaker implantation (RR, 2.03; 95% CI, 1.42–2.91) and major vascular complications (RR, 2.96; 95% CI, 1.50–5.86). No significant differences were observed in stroke, myocardial infarction, or major bleeding. The certainty of evidence ranged from very low to moderate. TAVR may offer advantages in early mortality and recovery but carries increased procedural risks, and treatment should be individualized through multidisciplinary Heart Valve Team assessment.
No takes yet. Share an insight, caveat, or question.
Nawaz et al. (2026) conducted a meta-analysis in Severe aortic stenosis in dialysis-dependent patients (n=13,312). Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated on 30-day all-cause mortality (RR 0.64, 95% CI 0.42–0.98). TAVR was associated with lower 30-day all-cause mortality than surgical aortic valve replacement in dialysis-dependent patients with severe AS.
Synapse has enriched 10 related papers. Consider them for comparative context: